Abstract
Aseptic loosening is one of the major causes of failure of artificial hip joints, and it can occur for several reasons, including osteolysis of the bone tissue in response to stress shielding or cellular reactions to wear debris. Any treatment of the prosthesis which could minimize the osteolytic response of bone tissue may be able to extend the life-time of the implant. Bisphosphonates are potent inhibitors of osteoclastic bone resorption, and they bind avidly to hydroxyapatite (HA). Coating the prostheses with bisphosphonates may therefore inhibit osteolysis. We have investigated the potential for this approach by determining whether bisphosphonates interact with osteoblasts in vitro. The effects of pamidronate (P), clodronate (C), and etidronate (E) in solution and when coated onto HA were investigated. P inhibited protein and collagen syntheses potently when in solution, but not after being bound to HA. When bound to HA, both P and C increased DNA, protein and collagen syntheses of osteoblasts and may encourage the osseointegration of implants. The pharmacological effects of the bisphosphonates studied altered dramatically after binding to HA. This must be fully investigated before this approach to prolonging prostheses stability can be evaluated.
Similar content being viewed by others
References
Report. Department of health research and development directorate (1995) p. 7.
E. Ingham and J. Fisher, Proc. Instn. Mech. Eng. 214 (2000) 21.
P. M. Boonekamp, L. J. A Van Der Wee-Pals, M. M. L. Van Wijk-Van Lennep, C. Wil Thesing and O. L. M. Bijvoet, Bone Miner. 1 (1986) 27-39.
A. Carano, S. L. Teitelbaum, J. D Konsek, P. H. Schlesinger and H. C. Blair. J. Clin. Invest. 85 (1990) 456-461.
M. G. Cecchini, R. Felix, H. Fleisch and P. H. Cooper, J. Bone Miner. Res. 2(2) (1987) 135-142.
D. E Hughes, M. Mian, D. F. Guilland-Cumming and R. G. G. Russell, Drugs Exptl. Clin. Res. 17(2) (1991) 109-114.
S. M. Horowitz, S. A. Algan and M. A. Purdon, J. Biomed. Mater. Research 31 (1996) 91-96.
C. W. G. M. Lowik, G. Van Der Pluijm, L. J. A. Van Der Wee-Pals, H. Bloys Van Treslong-De Groot and O. L. M. Bijvoet, J. Bone Miner. Res. 3(2) (1988) 185.
M. J. Rogers, D. J. Watts, R. Graham and R. Russell, Amer. Cancer Soc. (1997).
G. A. Rodan, Annu. Rev. Pharmacol. Toxicol. 38 (1998) 375-88.
S. Adami and N. Zamberlan, Drug Safety 14 (1996) 158.
H. Fleisch, “Bisphosphonates in Bone Disease. From the Laboratory to the Patient” (Parthenon Publishing, 1995).
M. Yoshinari, Y. Oda, H. Ueki and S. Yokose, Biomaterials 22 (2001) 709-715
H. Fleisch, Bone 8(1) (1987) 23.
A. Goziotis, B. Sukhu, M. Torontali, M. Dowhaniuk and H. C. Tenenbaum, ibid. 16(4) (1995) 317S-327S.
K. Igarashi, M. Hirafuji, H. Adachi, H. Shinoda and H. Mitani, Prostogalndins, Leukotrienes and Essential Fatty Acids 56(2) (1997) 121-125.
M. A. Khokher and P. Dandona, Metabolism 38(2) (1989) 184-187.
M. Tsuchimoto, Y. Azuma, O. Higuchi, I. Sugimoto, N. Hirata, M. Kiyoki and I. Yamamoto, Jpn. J. Pharmacol. 66 (1994) 25-33.
R. Macnair, R. Wilkinson, C. Macdonald, I. Goldie, D. Jones and M. H. Grant, Cells Mater. 6 (1996) 71.
R. Macnair, H. Rodgers, C. Macdonald, A. Wykman, I. Goldie and M. H. Grant, J. Mat. Sci.: Mat. Med. 8 (1997) 105.
C. Morrison, R. Macnair, C. Macdonald, A. Wykman, I. Goldie and M. H. Grant, Biomaterials 16 (1995) 987.
P. J. Hissin and R. Hilf, Anal. Biochem. 74 (1976) 214.
O. H. Lowry, N. J. Rosebrough, A. L. Farr and R. J. Randall, J. Biol. Chem. 193 (1951) 265.
Q. Shi, J. D. S. Gaylor, R. Cousins, J. Plevris, P. C. Hayes and M. H. Grant, Artif. Organs. 22 (1998) 1023.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ganguli, A., Henderson, C., Grant, M.H. et al. The interactions of bisphosphonates in solution and as coatings on hydroxyapatite with osteoblasts. Journal of Materials Science: Materials in Medicine 13, 923–931 (2002). https://doi.org/10.1023/A:1019892109411
Issue Date:
DOI: https://doi.org/10.1023/A:1019892109411